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Mitsuyoshi Azuma1,3, Chiho Yabuta1, Frederick W Fraunfelder2 and Thomas R Shearer3*Abstract
Background: Increasing age is a known risk factor for developing dry eye. The specific aims of the present study
were to determine the prevalence of dry eye syndrome (DES) and use of post-operative dry eye medications in a
relatively young population presenting for LASIK surgery at an academic ophthalmology clinic.
Findings: A retrospective, analysis of 948 de-identified patient charts (median age 39 years, not age stratified) was
performed to extract pre-LASIK diagnoses and post-LASIK medication lists. Clinical evaluation for DES and the results
of Schirmer’s reflex tear flow test were used to assign LASIK patients into Normal, Pre-dry eye (Pre-DES), and Dry
Eye Syndrome (DES) groups; which were then compared for use of dry eye medications.
Based on pre-operative diagnoses, only 2% (CI: 1.3 – 3.1) of LASIK patients presented with overt DES. Unexpectantly,
25% (CI: 22.2 – 27.6) of LASIK patients labeled Pre-DES were not classified by the clinician as having overt DES, yet
they showed poor reflex tear flow rates ≤ 5 mm before surgery, and frequently used post-operative lubricant dry
eye medications.
Conclusions: Although the number of patients with pre-existing eye conditions was unknown, a sizable portion of
relatively young LASIK patients displays poor reflex tear flow without overt DES. Such patients could go on to
develop more serious consequences of poor tear flow, such as corneal abrasion and erosion. More specific, dry eye
medications may be needed for ideal treatment.
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Background
Dry eye is a multifactorial disease of the tears and ocular
surface characterized by ocular discomfort visual distur-
bances, and potential erosion of the cornea. The underlying
physiologic mechanism is believed to be an escalating cycle
of interaction between tear film instability and tear film
hyperosmolarity [1]. Activation of this self-enhancing cycle
can be caused by many factors including LASIK-induced
anesthesia of the corneal-lacrimal gland reflex, aged-related
decreased tear production, diabetes associated neuropathy
and microvascular changes, meibomian gland dysfunction,
systemic and topical medications (β-blockers and atropine-
like drugs), autoimmune acinar damage in Sjögren’s
syndrome, herpes/HIV infections, and allergies [1].
The prevalence of dry eye in the US, Australia, and Asia
comprising a total of 73,899 patients from 8 epidemiologic
studies, ranged from 8 to 34% [2]. The vast majority of* Correspondence: shearert@ohsu.edu
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reproduction in any medium, provided the orthese patients were older than 40 years of age. Increasing
age is a known risk factor for developing dry eye [2]. Obvi-
ously, good clinical care would ameliorate dry eye before it
leads to corneal abrasion or impacts quality of life. We hy-
pothesized that a substantial number of patients receiving
LASIK would need continuing care for dry eye. Therefore,
the specific aims of the present study were to determine
the prevalence of dry eye and the use of post-operative dry
eye medications in the relatively young patients presenting
for LASIK surgery at an academic ophthalmology clinic.Methods
De-identified data were retrieved from medical charts
from patients presenting at the Casey Eye Institute at the
Oregon Health & Science University, according to a
protocol approved by the Oregon Health and Sciences
University Institutional Review Board and conducted in
compliance with the Declaration of Helsinki (2008). Me-
dian age was 39 years (range 18 – 72), 36% male and 43%
female (21% unknown), 83.3% of patients were Caucasian,
and the patients were not stratified by age. Since the med-
ical charts were anonymized, no consent was possible orLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Frequency of use of multiple dry eye medications
after LASIK. Numbers in () are total patients in each diagnostic group
used to calculate the “% Usage” within each group. The group
classification was based on the pre-operative diagnosis. Groups total >
100% because individual patients used more than one medication.
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relevant medical charts. Then the diagnosis (before LA-
SIK) and the most recent medications list after LASIK
were extracted from each chart in one computer search.
Depending on where the patient was in his recovery, the
medication lists would thus be at different times points
between different patients, usually within 90 days, and
always after LASIK. Schirmer’s reflex tear flow was per-
formed without anesthesia [3] before LASIK, using ≤
5 mm, as an indication of poor reflex tear flow. One
ophthalmologist, with knowledge of the Schirmer’s test
results, diagnosed DES (FWF).
Results
Of the total 948 patients undergoing pre-screening exams
prior to LASIK surgery, only 2% had been diagnosed with
DES and had low Schirmer’s reflex tear flow test values ≤
5 mm (Table 1, first row). Another 4% were diagnosed
with clinical DES but had adequate Schirmer’s reflex tear
flow values (second row). The large number of patients
(25%) not diagnosed with clinical DES but showing poor
Schirmer’s reflex tear flow values (3rd row), were classified
as susceptible to development of DES, and were labeled
Pre-DES. Sixty-nine% of the patients presenting for LASIK
surgery were “normal” in that they were clinically diag-
nosed as non-DES and had adequate Schirmer’s reflex tear
flow values (4th row).
After LASIK, the anti-inflammatory agent cyclosporine
A (CsA) was used frequently by DES patients (Figure 1
grey and cross hatched bars), but not by the large group of
Pre- DES patients (Figure 1, stippled bars). We also found
that non-dry eye patients as well as DES patients used
lubricant dry eye medications frequently. For example, arti-
ficial tears and gels use was very popular in both groups.
Discussion
The current study found that a cumulative total of 31% of
patients in this relatively young group of patients presentingTable 1 LASIK patients grouped according to dry eye
syndrome (DES) and Schirmer’s test values prior to
surgery
Diagnosis/Schirmer’s Patients % 95% CI4
DES1/≤5 mm 19 2 1.3 – 3.1
DES/>5 mm 39 4 3.0 – 5.6
Pre-DES2/≤5 mm 235 25 22.2 – 27.6
Non-DES3/>5 mm 655 69 66.1 – 72.0
Total 948 100
1DES was diagnosed in one or both eyes by a clinical ophthalmologist using:
patient complaint, Schirmer’s reflex tear flow test, and fluorescein corneal
surface staining (when appropriate).
2Pre-DES: ≤5 mm on Schirmer’s test in either eye and not diagnosed as DES.
3Non-DES: >5 mm on Schirmer’s test in either eye and not diagnosed as DES.
495% confidence interval based on binomial distribution was calculated with
JMP ver. 10.0.2 (SAS Institute, Cary, NC, USA).for LASIK surgery were affected to some degree by signs or
symptoms associated with DES (Table 1, italic area).
This was especially surprising in the large group of
patients labeled Pre-DES, who were not classified by the
clinician as having overt DES, but who showed poor Schir-
mer’s reflex tear flow rates ≤ 5 mm. This is important be-
cause at least some of these patients would presumably go
onto develop more serious consequences of poor tear flow
such as corneal abrasion and erosion. A limitation of the
current study was the number of patients with preexisting
eye conditions was unknown.
The data also beg the question as to what preventive
actions or medications should be administered to pre-
vent these sequelae.
OTC artificial tears and gels were very popular in DES,
Pre-DES, even in the Non-DES groups. The effectiveness
of popular artificial tears used by pre-dry eye and dry eye
LASIK patients will become limited if their symptoms
progress. Other medications, having different mechanisms
of action and possibly fewer side effects may be useful.
These may include lacritin [4], PACAP (pituitary adenylate
cyclase-activating peptide [5], and FK962 (N- (1-acetylpi-
peridin-4-yl)- 4-fluorobenzamide) [6].
Conclusions
With the propensity of LASIK to exacerbate dry eye, more
specific and/or customized medications for dry eye, such
as those presented above, may be needed for the future.Consent
Anonymized data only; no consent needed.
Abbreviations
CsA: Cyclosporine A, prescription anti-inflammatory agent inhibits lymphocyte
activation; Ster: Steroids, prescription methylyprednisolone-receptor complex
binds to DNA, to trigger anti-inflammatory and immunosuppressive responses;
Art Tr: Artificial tears; OTC: Over-the-counter, buffered electrolyte solutions/
viscosity agents; Gel: Gels OTC linked HMW polymers of acrylic acid to
increase retention times; Oils: OTC mineral oils and petrolatum to increase
tear film viscosity.
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